The multi-stakeholder Groundwork dialogue was designed to discuss and work through some of the challenges, both technical and political, of setting up and running processes for evidence-based decision-making in health systems within low- and middle-income countries.

Evidence-based decision-making is an important policy tool that many low- and middle-income countries are beginning to put in place, which could provide important public health benefits as well as greater predictability for pharmaceutical companies. However, the context of mistrust between health systems and the pharmaceutical industry in some places means that there is a danger that this tool will not reach its full potential. To avoid this outcome, health system personnel and pharmaceutical companies will need to establish a tone and process of constructive engagement that identifies potential flashpoints and permits the navigation and resolution of differences.

In this dialogue, Meteos brought together senior individuals and advisors from Colombia, Ghana, Philippines, Thailand and Vietnam health ministries; executives from Eli Lilly, GlaxoSmithKline and Janssen Pharmaceuticals (Johnson & Johnson); and priority-setting experts from NICE International, the Health Intervention and Technology Assessment Program (HITAP) and the Center for Global Development (CGD). The group looked at methodology and approaches, identified specific areas for engagement, and demonstrated the type of open, honest and constructive dialogue required for the introduction of robust evidence-based decision-making. Groundwork was designed to complement and reinforce other initiatives working to support healthcare priority setting in these countries.

The Groundwork group met twice for two workshops in the period March 2014 to April 2015 during which the group constructed a framework for collaborative evidence-based decision-making. The resulting Groundwork Framework was launched at a High-Level Meeting in Hanoi in April 2015. It is hoped that a contribution of this kind will help to set a leadership tone that encourages others to adopt a similar, collaborative approach.

The project is funded by the UK’s Department for International Development.

Who is involved?

Country Health Systems
Edith Gavor, Programme Manager, Ghana National Drugs Programme
Martha Gyansa-Lutterodt, Director Pharmaceutical Services, Ghana National Drugs Programme
Kenneth Hartigan-Go, Adjunct Faculty, Dr. Stephen Zuellig Graduate School of Development Management, Asian Institute of Management, Philippines
Sylvester Mensah, Chief Executive, National Health Insurance Agency, Ghana
Ana Lucia Munoz Mejia, Social Sector Specialist,Inter-American Development Bank (IDB), Colombia
Ong The Due, Researcher, Health Strategy and Policy Institue (HSPI), Ministry of Health, Vietnam
Nathaniel Otoo, Vice Chief Executive, National Health Insurance Agency, Ghana
Madeleine de Rosas-Valera, Assistant Secretary, Department of Health, The Philippines
Netnapis Suchonwanich, Assistant Secretary General, National Health Security Office, Thailand
Nguyen Khanh Phuong, Head of Health Economics Department, Health Strategy and Policy Institute (HSPI), Ministry of Health, Vietnam
Peerapol Sutiwisesak, Deputy Secretary General, National Health Security Office, Thailand
Dr Jadej Thammatacharee, Director of Policy and Planning, National Health Security Office, Thailand
Tran Thi Mai Oanh, Director, Health Strategy and Policy Institute (HSPI), Ministry of Health, Vietnam
Claudia Patricia Vaca Gonzalez, Consultant, Ministry of Health on Pharmaceutical Policy, Colombia
HTA/ Priority Setters
Kalipso Chalkidou, Founding Director, NICE International
Amanda Glassman, Director of Global Health Policy and a Senior Fellow, Centre for Global Development
Reetan Patel, Programme Manager, NICE International
Yot Teerawattananon, Program Leader and Senior Researcher, Health Intervention and
Technology Assessment Program, Thailand
Nattha Tritasavit, International Coordinator, Health Intervention and Technology Assessment
Program, Thailand
Pharmaceutical Companies
David Grainger,Senior Director, Global Public Policy, Eli Lilly
Jane Griffiths, Company Group Chairman, Janssen Pharmaceuticals, Europe, Middle East and Africa, Johnson & Johnson
Anjali Radcliffe, Director, Government Affairs, Europe, Middle East and Africa, GlaxoSmithKline
Chris Strutt, Senior Vice President, Government Affairs, Public Policy and Patient Advocacy, GlaxoSmithKline
Elisabeth Dell Kingsford Smith , Vice President, Global Pharmaceutical Pricing, Johnson & Johnson
Koen Torfs, Vice President Health Economics, Market Access and Reimbursement, Europe, Middle East and Africa, Johnson and Johnson
Steve Wooding, Managing Director Emerging Markets, Europe, Middle East and Africa, Johnson & Johnson

Related Resources

The Groundwork Framework: Seven Steps to Successful Healthcare Priority-Setting
•  Pathways to Value: Pharma in a Changing World
Interview with Sophia Tickell on the key conclusions of the latest PharmaFutures dialogue
For further information on Groundwork, please contact: